glp-1 receptor agonist with dpp-4 inhibitor combination not recommended Frontiers dpp-4_inhibitors [TUSOM | Pharmwiki]

The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function

Another large-scale cohort study demonstrated that long-term GLP-1RA use was associated with a more than twofold, exposure-dependent increase in the risk of developing nAMD

Tirzepatide is approved as Mounjaro for T2D and as Zepbound for chronic weight management and, notably by the FDA, for treatment of moderate to severe OSA in adults with obesity

Screening process We imported the database retrieved items into EndNote 20.4.1 (Clarivate Analytics, Philadelphia, PA, USA) and removed duplication, juxtaposing them with results from other sources

Cardiovascular Bottom Line Both Trulicity and Ozempic provide proven cardiovascular protection, making them preferred options for diabetic patients with cardiovascular disease or risk factors